

SUPPORTING INFORMATION

Alkaloid inspired spirocyclic oxindoles from 1,3-dipolar cycloaddition of pyridinium ylides

Jonathan Day,^a Maliha Uroos,^a Richard A. Castledine,^a William Lewis,^a Ben McKeever-Abbas,^b and James Dowden,^{*a}

^a*School of Chemistry, University of Nottingham, University Park, Nottingham, UK NG7 2RD.*


E-mail: james.dowden@nottingham.ac.uk; Fax: +44 115 9513565; Tel: +44 115 9513566.

^b*Pharmaceutical Development, AstraZeneca, Silk Road Business Park, Macclesfield, U.K.*

1. General Procedure for 2-oxoindolin-3-ylidenes by Wittig reaction:

To a stirred solution of the substituted isatin (1.0 equiv.) in anhydrous THF was added ethyl 2-(triphenylphosphoranylidene) acetate (1.2 equiv.) at 0 °C. The mixture was stirred at room temperature until the reaction was completed by TLC analysis. Water was added and the mixture extracted into ethyl acetate (3 x) and washed with sat. NH₄Cl_(aq), water, brine, dried over Na₂SO₄, filtered and evaporated *in vacuo*. The crude product was purified by column chromatography (EtOAc/Petrol; 1/1).


(E)-ethyl 2-(5-nitro-2-oxoindolin-3-ylidene)acetate 1c



Yellow solid; 545 mg (80 %); m.p. 176-178 °C (ethanol); IR ($\nu_{\max}/\text{cm}^{-1}$, CHCl₃) 3436, 3012, 1745, 1717, 1623, 1529, 1467, 1343, 1289, 1192; NMR δ_{H} (400 MHz, *d*⁶-acetone) 10.31 (1H, br s, NH), 9.45 (1H, d, *J* = 2.4 Hz, ArH), 8.32 (1H, dd, *J* = 8.7, 2.4 Hz, ArH), 7.17 (1H, d, *J* = 8.7 Hz, ArH), 6.83 (1H, s, C=CH), 4.38 (2H, q, *J* = 7.1 Hz, CH₂CH₃), 1.39 (3H, t, *J* = 7.1 Hz, CH₂CH₃); NMR δ_{C} (100 MHz, *d*⁶-DMSO) 168.4 (C), 165.2 (C), 151.0 (C), 142.5 (C), 136.9 (C), 129.5 (CH), 124.1 (CH), 123.9 (CH), 120.1 (C), 111.0 (CH), 62.0 (CH₂), 14.4 (CH₃); *m/z* (HRMS-ESI⁺) 285.0470 (M+Na C₁₂H₁₀N₂NaO₅ requires 285.0482).

SUPPORTING INFORMATION


5-methoxy-1-(prop-2-yn-1-yl)indoline-2,3-dione



Propargyl bromide (0.61 mL, 6.77 mmol; 80 % solution in toluene), 5-methoxy isatin (1.0 g, 5.64 mmol) and K_2CO_3 (1.09 g, 7.90 mmol) were stirred in acetonitrile (20 mL) at 65 °C for 4 h, followed by stirring at room temperature for 16 h. Solvent was removed *in vacuo* and the residue purified by column chromatography on silica gel (EtOAc/Petrol; 1/1) to give the product as a red solid (430 mg, 36%); m.p. 130-132 °C; IR ($\nu_{\max}/\text{cm}^{-1}$, CHCl_3) 3307, 2962, 1737, 1623, 1602, 1492, 1437, 1332, 1274, 1180, 1021; NMR δ_{H} (400 MHz, d^6 -DMSO) 7.33 (1H, dd, $J= 8.8, 2.8$ Hz, ArH), 7.19 (1H, d, $J= 2.8$ Hz, ArH), 7.18 (1H, d, $J= 8.8$ Hz, ArH), 4.53 (2H, d, $J= 2.5$ Hz, CH_2), 3.34 (1H, t, $J= 2.5$ Hz, CCH), 3.32 (3H, s, OCH_3); NMR δ_{C} (100 MHz, d^6 -DMSO) 183.2 (C), 157.9 (C), 156.5 (C), 143.7 (C), 124.4 (CH), 118.6 (C), 112.7 (CH), 109.7 (CH), 77.9 (C), 75.4 (CH), 56.4 (CH_3), 29.5 (CH_2); m/z (HRMS-ESI+) 238.0476 (M+Na $\text{C}_{12}\text{H}_9\text{NO}_3\text{Na}$ requires 238.0475).

SUPPORTING INFORMATION

(*E*)-ethyl 2-(5-methoxy-2-oxo-1-(prop-2-yn-1-yl)indolin-3-ylidene)acetate **1d**




5-Methoxy, *N*-propargyl isatin was converted to **1d** using the general procedure described above and the product was obtained as dark red solid, 171 mg (65%); m.p. 128-130 °C (ethanol); IR ($\nu_{\max}/\text{cm}^{-1}$, CHCl_3) 3306, 3011, 1708, 1596, 1482, 1437, 1371, 1291, 1192; NMR δ_{H} (400 MHz, d^6 -DMSO) 8.07 (1H, d, $J= 2.4$ Hz, ArH), 7.12 (1H, dd, $J= 8.6, 2.4$ Hz, ArH), 7.08 (1H, d, $J= 8.6$ Hz, ArH), 6.71 (1H, s, C=CH), 4.55 (2H, d, $J= 2.5$ Hz, CH_2), 4.28 (2H, q, $J= 7.1$ Hz, CH_2CH_3), 3.76 (3H, s, OCH_3), 3.29 (1H, t, $J= 2.5$ Hz, $\text{C}\equiv\text{CH}$), 1.30 (3H, t, $J= 7.1$ Hz, CH_2CH_3); NMR δ_{C} (100 MHz, d^6 -DMSO) 166.1 (C), 165.3 (C), 155.8 (C), 138.2 (C), 137.5 (C), 122.9 (CH), 120.2 (C), 118.4 (CH), 114.7 (CH), 110.8 (CH), 78.2 (C), 75.0 (CH), 61.7 (CH_2), 56.1 (CH_3), 29.5 (CH_2), 14.5 (CH_3); m/z (HRMS-ESI+) 308.0876 ($\text{M}+\text{Na}$ $\text{C}_{16}\text{H}_{15}\text{NNaO}_4$ requires 308.0893).

SUPPORTING INFORMATION

2. General Procedure A or B for the preparation of pyridinium salts:

An α -halocarbonyl (1 equiv.) and substituted pyridine (1 equiv.) in dry ethyl acetate were stirred overnight under argon at room temperature (A) or at reflux (B). Diethyl ether was added and the resulting precipitates filtered, washed with diethyl ether and recrystallised from ethanol.


3-bromo-1-(2-ethoxy-2-oxoethyl)pyridin-1-ium bromide 2a



Procedure A. White solid; 4.10 g (80 %); m.p. 177-179 °C; IR_{Solid} ($\nu_{\max}/\text{cm}^{-1}$) 2955, 1748, 1485, 1348, 1300, 1240; NMR δ_{H} (400 MHz, D₂O) 9.11 (1H, s, ArH), 8.81 (2H, m, ArH), 8.01 (1H, dd, $J= 8.4, 6.2$ Hz, ArH), 5.51 (2H, s, CH₂), 4.26 (2H, q, $J= 7.2$ Hz, CH₂CH₃), 1.22 (3H, t, $J= 7.2$ Hz, CH₂CH₃); NMR δ_{C} (100 MHz, D₂O) 166.7 (C), 149.7 (CH), 147.0 (CH), 144.7 (CH), 128.6 (CH), 122.8 (C), 64.2 (CH₂), 61.0 (CH₂), 13.2 (CH₃); m/z (HRMS-ESI+) 243.9961 ($\text{M}^+ \text{C}_9\text{H}_{11}\text{NO}_2^{79}\text{Br}^+$ requires 243.9968), 245.9939 ($\text{M}^+ \text{C}_9\text{H}_{11}\text{NO}_2^{81}\text{Br}^+$ requires 245.9948).


SUPPORTING INFORMATION

3-Cyano-1-(2-ethoxy-2-oxoethyl)pyridin-1-ium bromide 2g



Procedure B. Dark yellow solid; 6.10 g (78 %); m.p. 152-154 °C; IR_{Solid} ($\nu_{\max}/\text{cm}^{-1}$) 3002, 2922, 2257, 1748, 1642, 1510, 1467, 1365, 1228, 1205, 1026; NMR δ_{H} (300 MHz, D₂O) 9.48 (1H, s, ArH), 9.23 (1H, dt, $J= 6.5, 1.3$ Hz, ArH), 9.11 (1H, dt, $J= 8.3, 1.3$ Hz, ArH), 8.34 (1H, dd, $J= 8.3$ Hz, 6.5 Hz, ArH), 5.66 (2H, s, CH₂), 4.30 (2H, q, $J= 7.2$ Hz, CH₂CH₃), 1.26 (3H, t, $J= 7.2$ Hz, CH₂CH₃); NMR δ_{C} (100 MHz, D₂O) 166.3 (C), 150.3 (CH), 149.8 (CH), 149.7 (CH), 129.1 (CH), 114.0 (C), 113.2 (C), 63.5 (CH₂), 61.7 (CH₂), 13.4 (CH₃); m/z (HRMS-ESI+) 191.0828 (M⁺ C₁₀H₁₁N₂O₂⁺ requires 191.0815).


3-Acetyl-1-(2-ethoxy-2-oxoethyl)pyridin-1-ium bromide 2i



Procedure B. Red brown solid (11.5 g, 99 %); m.p. 123-125 °C (acetone); IR ($\nu_{\max}/\text{cm}^{-1}$, CHCl₃) 2954, 1747, 1711, 1637, 1585, 1467, 1397, 1376, 1277, 1240, 1020; NMR δ_{H} (400 MHz, D₂O) 9.40 (1H, s, ArH), 9.10-8.98 (2H, m, ArH), 8.28-8.24 (1H, m, ArH), 5.63 (2H, s, CH₂), 4.28 (2H, q, $J= 7.0$ Hz, CH₂CH₃), 2.73 (3H, s, COCH₃), 1.28 (3H, t, $J= 7.0$ Hz, CH₂CH₃); NMR δ_{C} (100 MHz, D₂O) 196.0 (C), 166.8 (C), 148.6 (CH), 146.5 (CH), 145.9 (CH), 145.3 (CH), 135.8 (C), 64.2 (CH₂), 26.6 (CH₃), 13.2 (CH₃); m/z (HRMS-ESI+) 208.0985 (M+H C₁₁H₁₄NO₃ requires 208.0986).


SUPPORTING INFORMATION

3-Bromo-1-(2-oxopropyl)pyridin-1-ium chloride 2j



Procedure B. Brown solid; 3.40 g (72%); m.p. 188-190 °C (ethanol); IR_{Solid} ($\nu_{\text{max}}/\text{cm}^{-1}$) 3004, 1730, 1629, 1496, 1430, 1355, 1318, 1204, 1174; NMR δ_{H} (300 MHz, D₂O) 8.93 (1H, t, $J=1.2$ Hz, ArH), 7.77 (1H, dt, $J=8.5, 1.2$ Hz, ArH), 8.64 (1H, dt, $J=6.2, 1.2$ Hz, ArH), 7.99 (1H, dd, $J=8.5, 6.2$ Hz, ArH), 5.72 (2H, s, CH₂), 2.36 (3H, s, COCH₃); NMR δ_{C} (100 MHz, D₂O) 201.1 (C), 149.2 (CH), 146.8 (CH), 144.5 (CH), 128.5 (CH), 122.6 (C), 68.4 (CH₂), 26.7 (CH₃); m/z (HRMS-ESI+) 213.9867 (M^+ C₈H₉⁷⁹BrNO⁺ requires 213.9863), 215.9845 (M^+ C₈H₉⁸¹BrNO requires 215.9843).


1-(2-ethoxy-2-oxoethyl)-3-fluoropyridin-1-ium bromide 2k



Procedure B. Brown solid; 110 mg (36%); m.p. 90-92 °C; IR ($\nu_{\text{max}}/\text{cm}^{-1}$, CHCl₃) 2952, 1749, 1595, 1506, 1397, 1350, 1240, 1167; NMR δ_{H} (400 MHz, D₂O) 9.04 (1H, s, ArH), 8.79 (1H, d, $J=6.0$ Hz, ArH), 8.56 (1H, t, $J=6.0$ Hz, ArH), 8.24-8.19 (1H, m, ArH), 5.62 (2H, s, CH₂), 4.32 (2H, q, $J=7.1$ Hz, CH₂CH₃), 1.28 (3H, t, $J=7.1$ Hz, CH₂CH₃); NMR δ_{C} (100 MHz, D₂O) 213.5 (C), 162.0 (C), 143.1 (CH), 134.8 (CH, d, $J=50$ Hz), 129.6 (CH, d, $J=10$ Hz), 122.6 (C), 68.4 (CH₂), 26.7 (CH₃); m/z (HRMS-ESI+) 184.0793 (M^+ C₉H₁₁FNO₂⁺ requires 184.0768).


SUPPORTING INFORMATION

3-bromo-1-(cyanomethyl)pyridin-1-ium bromide 2m



Procedure A. Brown solid; 2.35 g (80 %); m.p. 171-173 °C; IR ($\nu_{\max}/\text{cm}^{-1}$, CHCl_3) 3054, 2260, 1601, 1239, 944; NMR δ_{H} (400 MHz, DMSO) 9.90 (1H, s, ArH), 9.44 (1H, d, $J= 6.1$ Hz, ArH), 9.02 (1H, app d, $J= 8.5$ Hz, ArH), 8.24 (1H, dd, $J= 8.5, 6.1$ Hz, ArH), 6.28 (2H, s, CH_2); NMR δ_{C} (100 MHz, DMSO) 149.7 (CH), 146.9 (CH), 144.5 (CH), 129.1 (CH), 122.1 (C), 114.0 (C), 47.2 (CH_2), 61.0 (CH_2), 13.2 (CH_3); m/z (HRMS-ESI+) 198.9713 (M^+ $\text{C}_7\text{H}_6\text{N}_2^{79}\text{Br}^+$ requires 198.9689), 196.9724 (M^+ $\text{C}_7\text{H}_6\text{N}_2^{81}\text{Br}^+$ requires 245.9948).

1-benzyl-3-bromopyridin-1-ium bromide 2n



Procedure A. white solid; 5.21 g (84 %); m.p. 150-152 °C; IR ($\nu_{\max}/\text{cm}^{-1}$, CHCl_3) 3071, 3048, 2948, 1602, 1483, 1240, 1156, 1029; NMR δ_{H} (400 MHz, DMSO) 9.76 (1H, s, ArH), 9.26 (1H, d, $J= 6.1$ Hz, ArH), 8.93-8.89 (1H, m, ArH), 8.13 (1H, dd, $J= 8.4, 6.1$, ArH), 7.64-7.59 (2H, m, ArH), 7.48-7.41 (3H, m, ArH), 5.88 (2H, s, CH_2); NMR δ_{C} (100 MHz, DMSO) 148.3 (CH), 145.9 (CH), 143.7 (CH), 133.8 (C), 129.4 (CH), 129.5 (CH), 129.1 (CH), 129.0 (CH), 122.3 (C), 63.2 (CH_2); m/z (HRMS-ESI+) 248.0074 (M^+ $\text{C}_{12}\text{H}_{11}\text{N}^{79}\text{Br}^+$ requires 248.0070), 250.0052 (M^+ $\text{C}_{12}\text{H}_{11}\text{N}^{81}\text{Br}^+$ requires 250.0049).

SUPPORTING INFORMATION

3. General Procedure for preparation of cycloadducts:

Base (2 equiv.) was added to substituted pyridinium salt (2 equiv.) in dry solvent, under argon and the mixture stirred at room temperature for 5 mins, followed by the addition of oxindole (1 equiv.). The reaction mixture was stirred at room temperature until reaction was complete by TLC analysis. Water was added and the organic layer separated, washed with water (2x), brine, dried over Na₂SO₄, filtered and evaporated. The crude products were purified *via* column chromatography (MeOH/CH₂Cl₂; 1/10 or EtOAc/Petrol; 1/1) or recrystallised with ethanol.

References for previously described compounds:

1a: Cao, S.-H., Zhang, X.-C., Wei, Y. and Shi, M. *Eur. J. Org. Chem.*, **2011**: 2668–2672.

1b: Malhotra, S., Balwani, S., Dhawan, A., Singh, B. K. et. al. *Med. Chem. Commun.*, **2011**,
2, 743-751



1e: Long, D. R.; *J. Het. Chem.*, **1978**, 15, 633-6.



1f: Watanabe, T.; Arisawa, M.; Narusuye, K.; Alam, M. S.; Yamamoto, K.; Mitomi, M.;



Ozoe, Y.; Nishida, A. *Bioorg. Med. Chem.* **2009**, 17, 94.



2h: Delaine, T.; Bernardes-Genisson, V.; Meunier, B.; Bernadou, J. *J. Org. Chem.* **2007**, 72, 675-678.



2l: Katritzky, A. R.; Grzeskowiak, N. E.; Alvarezbuilla, J. *J. Chem. Soc.-Perkin Trans. 1* **1981**, 1180-1185.






















































































































































d⁶ acetone (Crude)



* = Et₃N



σ = CH₂Cl₂








































Correction added in proof:

The ^{13}C data originally provided for pyridinium salt was incorrect and should have read:

1-(2-ethoxy-2-oxoethyl)-3-fluoropyridin-1-ium bromide 2k



Procedure B. Brown solid; 110 mg (36%); m.p. 90-92 °C; IR ($\nu_{\text{max}}/\text{cm}^{-1}$, CHCl_3) 2952, 1749, 1595, 1506, 1397, 1350, 1240, 1167; NMR δ_{H} (400 MHz, D_2O) 9.04 (1H, s, ArH), 8.79 (1H, d, $J = 6.0$ Hz, ArH), 8.56 (1H, t, $J = 6.0$ Hz, ArH), 8.24-8.19 (1H, m, ArH), 5.62 (2H, s, CH_2), 4.32 (2H, q, $J = 7.1$ Hz, CH_2CH_3), 1.28 (3H, t, $J = 7.1$ Hz, CH_2CH_3); NMR δ_{C} (100 MHz, D_2O) 166.6 (C), 159.3 (C, d, $J^{\text{C-F}} = 340$ Hz), 143.2 (CH, d, $J^{\text{C-F}} = 4$ Hz), 136.0 (CH, d, $J^{\text{C-F}} = 50$ Hz), 134.8 (CH, d, $J^{\text{C-F}} = 50$ Hz), 129.6 (CH, d, $J^{\text{C-F}} = 10$ Hz), 64.2 (CH_2), 61.4 (CH_2), 13.23 (CH_3); m/z (HRMS-ESI+) 184.0793 (M^+ $\text{C}_9\text{H}_{11}\text{FNO}_2^+$ requires 184.0768).